Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation

被引:102
作者
Landolfi, R. [1 ,2 ]
Di Gennaro, L. [1 ]
Falanga, A. [3 ]
机构
[1] Catholic Univ, Sch Med, Inst Internal Med & Geriatr, Haemostasis Res Ctr,Dept Internal Med, I-00168 Rome, Italy
[2] Res Inst Oasi Maria Santissima, Troina, Italy
[3] Osped Riuniti Bergamo, Haemostasis & Thrombosis Ctr, Dept Hematol Oncol, I-24100 Bergamo, Italy
关键词
essential thrombocythaemia; polycythaemia vera; myeloproliferative disorders; thrombosis; JAK2;
D O I
10.1038/leu.2008.253
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thrombophilia, which severely impacts on morbidity and mortality of polycythaemia vera and essential thrombocythaemia, is variably characterized by microcirculatory disturbances, arterial and venous thromboses that often precede disease recognition. Thus, the search for Janus Kinase 2 mutation, the molecular marker of myeloproliferative neoplasms, is becoming increasingly common particularly in patients with vein thromboses at atypical sites. Although the pathogenesis of thrombophilia is still elusive, platelet and leukocyte abnormalities seem particularly critical and likely account for the antithrombotic efficacy of aspirin and hydroxyurea.
引用
收藏
页码:2020 / 2028
页数:9
相关论文
共 94 条
[1]   Leukocyte adhesion and thrombosis [J].
Afshar-Kharghan, V ;
Thiagarajan, P .
CURRENT OPINION IN HEMATOLOGY, 2006, 13 (01) :34-39
[2]  
Afshar-Kharghan V, 2001, BLOOD, V98, p471A
[3]   Essential thrombocythemia in young individuals:: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients [J].
Alvarez-Larran, A. ;
Cervantes, F. ;
Bellosillo, B. ;
Giralt, M. ;
Julia, A. ;
Hernandez-Boluda, J. C. ;
Bosch, A. ;
Hernandez-Nieto, L. ;
Clapes, V. ;
Burgaleta, C. ;
Salvador, C. ;
Arellano-Rodrigo, E. ;
Colomer, D. ;
Besses, C. .
LEUKEMIA, 2007, 21 (06) :1218-1223
[4]   Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: Relationship with splanchnic vein thrombosis and arterial disease [J].
Amitrano, L ;
Guardascione, MA ;
Ames, PRJ ;
Margaglione, M ;
Antinolfi, I ;
Iannaccone, L ;
Annunziata, M ;
Ferrara, F ;
Brancaccio, V ;
Balzano, A .
AMERICAN JOURNAL OF HEMATOLOGY, 2003, 72 (02) :75-81
[5]  
Arellano-Rodrigo E, 2006, HAEMATOL-HEMATOL J, V91, P169
[6]  
BAKER RI, 1988, EUR J HAEMATOL, V95, P82
[7]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[8]   Major vascular complications in essential thrombocythemia:: a study of the predictive factors in a series of 148 patients [J].
Besses, C ;
Cervantes, F ;
Pereira, A ;
Florensa, L ;
Solé, F ;
Hernández-Boluda, C ;
Woessner, S ;
Sans-Sabrafen, J ;
Rozman, C ;
Montserrat, E .
LEUKEMIA, 1999, 13 (02) :150-154
[9]   Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis [J].
Boissinot, Marjorie ;
Lippert, Eric ;
Girodon, Francois ;
Dobo, Irene ;
Fouassier, Marc ;
Masliah, Claude ;
Praloran, Vincent ;
Hermouet, Sylvie .
BLOOD, 2006, 108 (09) :3223-3224
[10]   Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders:: Diagnosis and management [J].
Brière, JB .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (03) :208-218